|
- Blog: Riluzole, Edaravone, and Tofersen: The Approved Dru. . . | ALS TDI
There are currently no treatments to stop the progression of amyotrophic lateral sclerosis (ALS) However, there are now three drugs available that provide some benefits to people living with ALS Two drugs have been approved in the US for use by all people with ALS: riluzole and edaravone (Radicava) An additional drug, tofersen (Qalsody), was approved in early 2023 for use by people with
- FDA Approves Radicava (edaravone) as Treatment for ALS
Edaravone was developed by Mitsubishi Tanabe Pharma Corporation in Japan, originally as a treatment used in the recovery from stroke Later, the company worked through several clinical trials in Japan to explore its potential as a treatment for ALS given its properties as a free radical scavenger
- One Year in and 2500+ People on Radicava (Edaravone) - ALS TDI
It has been one year since Radicava (edaravone) was approved by the FDA to be marketed as a treatment for ALS This brief commentary reflects on the last year and offer some thoughts and opinions from people with ALS and ALS researchers since the approval
- Blog: Radicut® Approved for ALS in Japan | ALS TDI
Mitsubishi Tanabe Pharma Corporation announced recently that it has received approval to market Radicut® (aka Edaravone or MCI-186) for the treatment of ALS in Japan The regulatory agency in that country, the Pharmaceutical and Medical Device Agency (PMDA), approved Radicut on June 26, 2015, and the approval is strictly limited to Japan
- Blog: Chris Spaulding: Fighting for Access to FDA-Approve. . . | ALS TDI
Of course, anyone familiar with ALS is likely aware that, for the vast majority of people with the disease, there are no effective treatments to slow or stop progression However, there are two FDA-approved drugs that have been shown to provide some benefits for people with ALS— edaravone, sold under the brand name Radicava, and riluzole
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects . . .
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS) based on the change in A
- Trial: Efficacy and Safety Extension Study of Oral Edarav. . . | ALS TDI
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from
- Trial: Safety Extension Study of Oral Edaravone Administe. . . | ALS TDI
The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) for up to 96 weeks
|
|
|